Larissa Camargo da Rosa

Larissa Camargo da Rosa

Auto-generated profile, based on publicly available information

Larissa Camargo da Rosa

Department of Structural and Functional Biology, Institute of Biology, University of Campinas, UNICAMP, Campinas, SP, Brazil

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2019 in Cellular & Molecular Immunology
Verified
Journal Article
Open access
PDF file
JBJoanne Boldison
Joanne Boldison
LRLarissa Camargo Da Rosa
Larissa Camargo Da Rosa
JDJoanne Davies
Joanne Davies
LWLi Wen
Li Wen
FWF. Susan Wong
F. Susan Wong
Regulatory B cells (Bregs) suppress and reduce autoimmune pathology. However, given the variety of Breg subsets, the role of Bregs in the pathogenesis of type 1 diabetes is still unclear. Here, we dissect this fundamental mechanism. We show that natural protection from type 1 diabetes in nonobese diabetic (NOD) mice is associated with increased numbers of IL-10-producing B cells, while development of type 1 diabetes in NOD mice occurs in animals with compromised IL-10 production by B cells. However, B cells from diabetic mice regain IL-10 function if activated by the innate immune receptor TLR4 and can suppress insulin-specific CD8 T cells in a dendritic cell (DC)-dependent, IL-10-mediated fashion. Suppression of CD8 T cells is reliant on B-cell contact with DCs. This cell contact results in deactivation of DCs, inducing a tolerogenic state, which in turn can regulate pathogenic CD8 T cells. Our findings emphasize the importance of DC–Breg interactions during the development of type 1 diabetes.

1 January 2013 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
SZSofia Fernanda Gonçalves Zorzella-Pezavento
Sofia Fernanda Gonçalves Zorzella-Pezavento
FCFernanda Chiuso-Minicucci
Fernanda Chiuso-Minicucci
TFThais Graziela Donegá França
Thais Graziela Donegá França
LILarissa Ishikawa
Larissa Ishikawa
LRLarissa Camargo da Rosa
Larissa Camargo da Rosa
ASAlexandrina Sartori
Alexandrina Sartori
Experimental autoimmune encephalomyelitis (EAE) is an artificially induced demyelination of the central nervous system (CNS) that resembles multiple sclerosis in its clinical, histopathological, and immunological features. Activated Th1 and Th17 cells are thought to be the main immunological players during EAE development. This study was designed to evaluate peripheral and local contribution of IL-17 to acute and chronic EAE stages. C57BL/6 mice were immunized with MOG plus complete Freund’s adjuvant followed by pertussis toxin. Mice presented an initial acute phase characterized by accentuated weight loss and high clinical score, followed by a partial recovery when the animals reached normal body weight and smaller clinical scores. Spleen cells stimulated with MOG produced significantly higher levels of IFN-γduring the acute period whereas similar IL-17 levels were produced during both disease stages. CNS-infiltrating cells stimulated with MOG produced similar amounts of IFN-γbut, IL-17 was produced only at the acute phase of EAE. The percentage of Foxp3+ Treg cells, at the spleen and CNS, was elevated during both phases. The degree of inflammation was similar at both disease stages. Partial clinical recovery observed during chronic EAE was associated with no IL-17 production and presence of Foxp3+ Treg cells in the CNS.

22 February 2019 in Diabetes
Verified
Journal Article
Closed access
PDF file
JPJames A. Pearson
James A. Pearson
DKDimitri Kakabadse
Dimitri Kakabadse
JDJoanne Davies
Joanne Davies
JPJian Peng
Jian Peng
JWJeremy Warden-Smith
Jeremy Warden-Smith
FWF. Susan Wong
F. Susan Wong
Insulin is a major autoantigen in type 1 diabetes, targeted by both CD8 and CD4 T-cells. We studied an insulin-reactive T-cell receptor (TCR) alpha-chain transgenic non-obese diabetic (NOD) mouse on a TCRCα and proinsulin2 (PI2)-deficient background, designated as A22Cα-/-PI2-/-NOD mice. These mice develop a low incidence of autoimmune diabetes. To test the role of gut microbiota on diabetes development in this model system, we treated the A22Cα-/-PI2-/-NOD mice with enrofloxacin, a broad-spectrum antibiotic. The treatment led to male mice developing accelerated diabetes. We found that enrofloxacin increased the frequency of the insulin-reactive CD8+ T-cells and activated the cells in the Peyer’s patches (PP) and pancreatic lymph nodes (PLNs), together with induction of immunological effects on the antigen-presenting cell populations. The composition of gut microbiota differed between the enrofloxacin-treated and untreated mice and also between the enrofloxacin-treated mice that developed diabetes, compared with those that remained normoglycemic. Our results provide evidence that the composition of the gut microbiota is important for determining the expansion and activation of insulin-reactive CD8+ T-cells.

1 October 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
LTLivia de Lima Thomaz
Livia de Lima Thomaz
GPGabriela Peron
Gabriela Peron
JOJanine Oliveira
Janine Oliveira
LRLarissa Camargo da Rosa
Larissa Camargo da Rosa
RTRodolfo Thomé
Rodolfo Thomé
LVLiana Verinaud
Liana Verinaud

1 September 2011 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
ADAlexandre Domingues
Alexandre Domingues
ASAlexandrina Sartori
Alexandrina Sartori
MGMarjorie de Assis Golim
Marjorie de Assis Golim
LVLigia Maria Marino Valente
Ligia Maria Marino Valente
LRLarissa Camargo da Rosa
Larissa Camargo da Rosa
RVRosa Marlene Viero
Rosa Marlene Viero

28 March 2018 in Diabetologia
Verified
Journal Article
Open access
PDF file
LRLarissa C. Da Rosa
Larissa C. Da Rosa
JBJoanne Boldison
Joanne Boldison
ELEvy De Leenheer
Evy De Leenheer
JDJoanne Davies
Joanne Davies
LWLi Wen
Li Wen
FWF. Susan Wong
F. Susan Wong
Type 1 diabetes is a T cell-mediated autoimmune disease characterised by the destruction of beta cells in the islets of Langerhans, resulting in deficient insulin production. B cell depletion therapy has proved successful in preventing diabetes and restoring euglycaemia in animal models of diabetes, as well as in preserving beta cell function in clinical trials in the short term. We aimed to report a full characterisation of B cell kinetics post B cell depletion, with a focus on pancreatic islets.